Clinical Trial

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-02-02; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2024-07-15
Trial Details
NCT Number NCT06241781
Lead Sponsor Grit Biotechnology
Conditions Adult
Enrollment 83 participants
Start Date 2024-04-02
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15